Excellerant, Inc. (EXCL) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerExcellerant, Inc. (EXCL) trades at $0.0002. Excellerant, Inc. is a development stage company based in Brussels, Belgium, focusing on health advisory and tour services. Sector: Financials.
Price as of · Last analyzed: Mar 15, 2026Analyst Coverage for EXCL: EXCL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Excellerant, Inc. (EXCL) Financial Services Profile
Excellerant, Inc., operating as a development stage company within the financial services sector, provides health advisory and tour services. As a shell company based in Brussels and a subsidiary of Swamson Capital AG, Excellerant focuses on consulting and itinerary arrangement within traditional and alternative medicine, facing challenges typical of OTC-traded entities.
What Is the Investment Thesis for EXCL?
Excellerant, Inc. presents a high-risk, high-reward investment profile due to its status as a development stage company operating in the OTC market. With a market capitalization of $0.00B and negative P/E ratio of -0.08, the company's financials reflect its current lack of profitability. Key value drivers would depend on successful execution of its health advisory and tour service offerings. Growth catalysts include securing partnerships with medical institutions and expanding its client base. However, potential risks include limited operating history, dependence on its parent company, Swamson Capital AG, and the inherent volatility associated with OTC-traded stocks. Investors should carefully consider the speculative nature of this investment.
Based on FMP financials and quantitative analysis
EXCL Key Highlights
Market capitalization of $0.00B, reflecting its status as a development stage company.
- Negative P/E ratio of -0.08, indicating current lack of profitability.
- Beta of -7.67, suggesting high volatility and potential sensitivity to market movements.
- Operates with only 1 employee, highlighting its early stage and limited operational capacity.
- Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Who Are EXCL's Competitors?
EXCL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIIT Tianci International, Inc. | $2.58 | +4.03% | 32 5-pillar | |
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | 44 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.81 | -0.16% | $25.3M | 47 5-pillar |
| RIBB Ribbon Acquisition Corp | $7.40 | -7.04% | $36.2M | 42 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $12.28 | -0.81% | $51.4M | 47 5-pillar |
| IBAC IB Acquisition Corp. | $10.88 | -0.18% | $54.5M | 43 5-pillar |
| FVN Future Vision II Acquisition Corp. | $8.87 | +10.81% | $60.4M | 42 5-pillar |
| WTG Wintergreen Acquisition Corp. | $10.99 | +3.29% | $77.7M | 50 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EXCL's Key Strengths?
Specialized focus on health advisory and tour services.
- Potential for growth in the medical tourism market.
- Subsidiary of Swamson Capital AG providing financial backing.
- Personalized service approach.
What Are EXCL's Weaknesses?
Development stage company with limited operating history.
- Dependence on parent company for resources.
- Small team with only one employee.
- OTC market listing indicating higher risk.
What Are the Key Risks for EXCL?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited operating history and financial disclosure.
- High potential for price manipulation and fraud due to OTC listing.
- Dependence on parent company for funding and resources.
- Competition from established players in the consulting and travel industries.
- Economic downturn affecting medical tourism demand.
What Threats Does EXCL Face?
- Competition from established players in the consulting and travel industries.
- Economic downturn affecting medical tourism demand.
- Regulatory changes impacting healthcare and travel services.
- Volatility associated with OTC-traded stocks.
What Are EXCL's Competitive Advantages?
- Specialized knowledge in traditional and alternative medicine.
- Established network of medical institutions.
- Personalized service approach.
What Does EXCL Do?
Incorporated in 2019, Excellerant, Inc. is a development stage company headquartered in Brussels, Belgium. The company's primary focus is to offer health advisory and tour services, targeting both legal entities and individual clients. Excellerant aims to provide consulting services in traditional and alternative medicine, as well as medical technologies. Its service offerings include assisting customers in selecting clinics for treatment and arranging detailed itineraries that encompass clinics, hospitals, and other medical institutions. Excellerant also intends to offer guide services to potential clients and provide information related to transportation and medical facilities. As a subsidiary of Swamson Capital AG, Excellerant operates with a single employee and is traded on the OTC market, reflecting its early stage and limited operational scope. The company's business model is centered around facilitating medical tourism and advisory services, catering to a niche market within the broader healthcare sector.
What Products and Services Does EXCL Offer?
- Provides consulting services in traditional and alternative medicine.
- Assists customers in selecting clinics for medical treatment.
- Arranges detailed itineraries including clinics, hospitals, and medical institutions.
- Offers guide services to potential clients.
- Provides information related to transportation and medical facilities.
- Facilitates medical tourism by connecting patients with healthcare providers.
How Does EXCL Make Money?
- Generates revenue through consulting fees for health advisory services.
- Earns commissions from medical institutions for referrals.
- Charges fees for itinerary arrangement and guide services.
What Industry Does EXCL Operate In?
Excellerant, Inc. operates within the shell companies industry, a segment known for its speculative nature and potential for high volatility. The broader financial services sector is undergoing significant transformation, driven by technological advancements and changing consumer preferences. Excellerant's focus on health advisory and tour services positions it within the niche market of medical tourism, which is experiencing growth due to increasing globalization and demand for specialized healthcare services. However, the company faces competition from established players in the consulting and travel industries, as well as other shell companies seeking to capitalize on emerging market trends.
Who Are EXCL's Key Customers?
- Legal entities seeking health advisory services for their employees.
- Individuals seeking medical treatment abroad.
- Patients interested in traditional and alternative medicine.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Excellerant, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Brussels, BE. The company is led by CEO Roman Kopinski. EXCL has traded publicly since 2021.
Financial Health
Excellerant, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
EXCL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
EXCL Latest News
-
Samsung is the foldable phone king, with sales growing 30% and reviews praising its newest devices. Can it keep the crown as Apple enters the picture?
Fortune | FORTUNE · Sep 8, 2026
-
Excalibur Metals Defines New Silver-Gold Soil Anomalies North of Spyglass Ridge
newsfilecorp.com · Aug 11, 2026
EXCL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EXCL.
Price Targets
Wall Street price target analysis for EXCL.
EXCL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EXCL; grades run from A+ (80-100) to F (below 30).
Latest News
Leadership: Roman Kopinski
Managing Director
Roman Kopinski serves as the Managing Director of Excellerant, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing small teams and guiding early-stage companies. While specific details on his prior roles and educational qualifications are not available, his leadership is crucial for steering Excellerant through its development phase. He is responsible for shaping the company's business model and establishing its presence in the health advisory and tour services market.
Track Record: As the Managing Director, Roman Kopinski is responsible for guiding Excellerant, Inc. through its initial development stages. Given the company's recent incorporation in 2019 and its current focus on establishing its service offerings, his key achievements involve setting up the company's operational framework and initiating partnerships within the medical tourism sector. His strategic decisions will be critical in determining the company's future growth and market positioning.
EXCL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Excellerant, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks involves higher risks due to the potential for fraud, lack of liquidity, and limited information available to investors. This tier is typically reserved for companies that are distressed, in bankruptcy, or have chosen not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Limited operating history and financial disclosure.
- High potential for price manipulation and fraud.
- Lack of regulatory oversight compared to major exchanges.
- Dependence on parent company for funding and resources.
- Potential for delisting or suspension of trading.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Determine the source of capital for the company.
- Subsidiary of Swamson Capital AG.
- Incorporated in 2019.
- Focus on health advisory and tour services.
Common Questions About EXCL (Financials)
What do analysts say about EXCL stock?
As of 2026-03-15, there is no available analyst coverage or consensus on Excellerant, Inc. (EXCL) due to its status as a development stage company traded on the OTC market. Key valuation metrics such as price targets and earnings estimates are not available. Investors should conduct their own due diligence and consider the speculative nature of this investment.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's development stage and OTC listing.